fecal microbiota spores, live-brpk · VOWST

Microbiome therapeutic

Approved / Phase 4Mechanism not established
Approvedregulatory verdict

Evidence outlook

Approved: Recurrent Clostridioides Difficile Infection

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Recurrent Clostridioides Difficile Infection
Other / comorbidity
NCT03183128 · Seres Therapeutics, Inc.
Run by former owner Seres Therapeutics
2017-07-10 – 2020-09-29 · Clostridium Difficile Infection
What this study did
Phase 2 (1)
Other / comorbidity
NCT02437487 · Seres Therapeutics, Inc.
Run by former owner Seres Therapeutics
2015-05 – 2016-10 · Clostridium Difficile
What this study did

Competitive landscape

This drug's own stage for Recurrent Clostridioides Difficile Infection: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fecal Microbiota Spores, Live-Brpk (VOWST): this drugApprovedMicrobiome therapeutic—Weak signalNo reviewed efficacy summary in this indication
AZD5148
Phase 1(overall)
Monoclonal antibodyClostridioides difficile toxin B (TcdB)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.